Talha Munir

775 total citations · 1 hit paper
16 papers, 365 citations indexed

About

Talha Munir is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Talha Munir has authored 16 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 12 papers in Pathology and Forensic Medicine and 7 papers in Immunology. Recurrent topics in Talha Munir's work include Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (12 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Talha Munir is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (12 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Talha Munir collaborates with scholars based in United Kingdom, United States and Italy. Talha Munir's co-authors include Peter Hillmen, Jennifer R. Brown, Constantine S. Tam, Nishitha Reddy, Carol Moreno, John C. Byrd, Stephen P. Mulligan, James P. Dean, Paul M. Barr and Marco Montillo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Talha Munir

13 papers receiving 359 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

2019 307 citations Talha Munir, Jennifer R. Brown et al. American Journal of Hematology profile →

Peers

Talha Munir

GENET

PFM

IMMUN

HEMAT

PRM

Amber B. Koehler United States

George P. Keogh United States

Polina Kaplan Poland

Aileen Cohen United States

Thérèse Aurran France

Владимир Стругов Russia

Athanassios Zomas Greece

Laurie Musial United States

Ulrike Söling Germany

Geisler Ch Denmark

Amber B. Koehler United States

Talha Munir

290 ×0.9

GENET

219 ×0.8

PFM

82 ×0.6

IMMUN

69 ×0.7

HEMAT

43 ×0.9

PRM

Citations per year, relative to Talha Munir Talha Munir (= 1×) peers Amber B. Koehler

Countries citing papers authored by Talha Munir

Since Specialization

Citations

This map shows the geographic impact of Talha Munir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Talha Munir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Talha Munir more than expected).

Fields of papers citing papers by Talha Munir

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Talha Munir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Talha Munir. The network helps show where Talha Munir may publish in the future.

Co-authorship network of co-authors of Talha Munir

This figure shows the co-authorship network connecting the top 25 collaborators of Talha Munir. A scholar is included among the top collaborators of Talha Munir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Talha Munir. Talha Munir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Shadman, Mazyar, Talha Munir, Shuo Ma, et al.. (2025). Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results. Journal of Clinical Oncology. 43(21). 2409–2417. 3 indexed citations

Walewska, Renata, Toby A. Eyre, Adrian Bloor, et al.. (2025). 2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia. British Journal of Haematology. 207(6). 2296–2313.

Tam, Constantine S., Masa Lasica, Jacob D. Soumerai, et al.. (2025). 49 | COMBINATION TREATMENT WITH NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB‐11417) + ZANUBRUTINIB INDUCES HIGH RATE OF COMPLETE REMISSION IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA. Hematological Oncology. 43(S3). 1 indexed citations

Griffin, Morag, Richard Kelly, Petra Muus, et al.. (2024). Real‐world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. American Journal of Hematology. 99(5). 816–823. 17 indexed citations

Varghese, Abraham & Talha Munir. (2024). SOHO State of the Art Updates and Next Questions | Impact of Biologic Markers on Outcomes With Novel Therapy in Chronic Lymphocytic Leukaemia. Clinical Lymphoma Myeloma & Leukemia. 25(6). 381–394.

Niemann, Carsten Utoft, Talha Munir, Carolyn Owen, et al.. (2024). First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis. Blood. 144(Supplement 1). 1871–1871. 5 indexed citations

Lin, Ke, et al.. (2024). Measurable residual disease‐driven treatment in first‐line chronic lymphocytic leukaemia. British Journal of Haematology. 206(1). 33–43. 2 indexed citations

Martínez‐Calle, Nicolás, et al.. (2023). The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials. Frontiers in Oncology. 13. 1130617–1130617. 9 indexed citations

Tedeschi, Alessandra, Inhye E. Ahn, Graeme Fraser, et al.. (2023). Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials. Hematological Oncology. 41(S2). 461–463.

10.

Appleby, Niamh, et al.. (2023). Richter's transformation: Transforming the clinical landscape. Blood Reviews. 64. 101163–101163. 3 indexed citations

11.

Munir, Talha, et al.. (2023). Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States. Expert Review of Pharmacoeconomics & Outcomes Research. 23(5). 579–589. 4 indexed citations

12.

Jurczak, Wojciech, Nagah Elmusharaf, Christopher P. Fox, et al.. (2023). Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia. Therapeutic Advances in Hematology. 14. 1564091249–1564091249. 3 indexed citations

13.

Munir, Talha, Anna Hockaday, Dena Howard, et al.. (2022). Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial. British Journal of Haematology. 199(5). 707–719. 4 indexed citations

14.

Macrae, Fraser L., Stephen R. Baker, Peter Hillmen, et al.. (2020). Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab. American Journal of Hematology. 95(8). 944–952. 6 indexed citations

15.

Munir, Talha, Jennifer R. Brown, Susan O’Brien, et al.. (2019). Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology. 94(12). 1353–1363. 307 indexed citations breakdown →

16.

Munir, Talha, Andy C. Rawstron, Kristian Brock, et al.. (2018). Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy. British Journal of Haematology. 181. 34–35. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact